Story perspectives

Novartis Strikes $5.7B Deal, Boosts Monte Rosa Shares

9/15/2025

47 4

Summary

Story summary

Novartis has entered a $5.7 billion licensing deal with Monte Rosa Therapeutics to develop drugs for immune-mediated diseases.
The deal includes a $120 million upfront payment and potential milestone payments.
Monte Rosa will use its AI-powered QuEEN platform to discover molecular glue degraders.
Following the announcement, Monte Rosa's shares rose 33%, indicating strong investor confidence.
Novartis secures exclusive rights to an undisclosed target and options for two preclinical programs.

1 of 1

Story summary

Novartis has entered a $5.7 billion licensing deal with Monte Rosa Therapeutics to develop drugs for immune-mediated diseases.
The deal includes a $120 million upfront payment and potential milestone payments.
Monte Rosa will use its AI-powered QuEEN platform to discover molecular glue degraders.
Following the announcement, Monte Rosa's shares rose 33%, indicating strong investor confidence.
Novartis secures exclusive rights to an undisclosed target and options for two preclinical programs.